ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Hanmi scraps development of lung cancer drug Olita in face of competition from AstraZeneca's Tagrisso
April 16, 2018Hanmi Pharmaceutical announced Friday that it will end development of the lung cancer therapy Olita (olmutinib) due to difficulties recruiting patients for pivotal studies and the cancellation of licensing deals for the third-generation tyrosine kinase in
Pharma Sources Insight January 2025
